Newsletter Tool

PM Tracker

Today’s Big News

Aug 23, 2024

Biopharma VC hits highest level since 2022, but challenges in exit landscape remain

Bicara and Zenas file for IPOs to push late-phase prospects toward finish line

Bayer layoffs hit Switzerland with 150 cuts at Basel consumer health hub

As sales climb, Jazz's Epidiolex falls short in Japanese study in treatment-resistant epilepsies

Procept Biorobotics stock jumps on FDA nod for prostate surgery system

Featured

Biopharma VC hit highest quarterly level since 2022, but challenges in exit landscape remain

By Gabrielle Masson

Venture capital in biopharma rose to $9.2 billion across 215 deals in the second quarter of this year, reaching the highest funding level since the same quarter in 2022.

Bicara and Zenas file for IPOs to push late-phase prospects toward finish line

By Nick Paul Taylor

Bicara Therapeutics and Zenas Biopharma have provided fresh impetus to the IPO market with filings that illustrate what newly public biotechs may look like in the back half of 2024.

Bayer layoffs hit Switzerland with 150 cuts at Basel consumer health hub

By Zoey Becker

The layoffs are the latest in Bayer's massive restructuring plan that has so far impacted more than 3,000 staffers since the start of the year.

As sales climb, Jazz's Epidiolex falls short in Japanese study in treatment-resistant epilepsies

By Fraiser Kansteiner

On Friday, Jazz revealed that its Epidiolex oral solution failed to mass muster in a late-stage study when used as an adjunct treatment for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS) or tuberous sclerosis complex (TSC) in young Japanese patients.

Procept Biorobotics stock jumps on FDA nod for prostate surgery system

By Heather Landi

Procept Biorobotics shares soared 30% on Wednesday after the company said its robotic system designed to treat benign prostatic hyperplasia received clearance from the Food and Drug Administration (FDA).

Understanding how pythons swallow massive meals may help develop new human heart medicines

By Darren Incorvaia

To digest large, infrequent feasts, a python's heart works overtime by increasing oxygen use, pumping more blood and swelling in size. This rapid response requires a heart that is soft and flexible, the opposite of the stiff and fibrous heart that is characteristic of many human cardiac diseases.

FDA signs off on Modena, Pfizer/BioNTech's adapted vaccines to corral elusive COVID virus

By Kevin Dunleavy

The FDA has authorized the use of new vaccines from Pfizer/BioNTech and Moderna which have been designed to defend against the Omicron KP.2 variant of SARS-CoV-2. The nod comes as word of a new omicron variant, KP.3.1.1, is beginning to eclipse KP.2 as the dominant strain of the virus in the United States.

Chutes & Ladders—BioMarin builds executive team with biotech vets

By Darren Incorvaia,Zoey Becker,Gabrielle Masson

The coastal California biotech BioMarin is bringing two biotech vets on board to lead its new-look R&D and deals teams.

Fierce podcasts

Don’t miss an episode

What Chevron’s overturn means for biopharma

This week on "The Top Line," we look at the potential effects of the Chevron overturn on the biopharma industry.

How incentives engage and keep patients healthy

The TROP2 race for supremacy

Resources

Whitepaper

Launching a Product in Europe: Understanding Supply Chain Cost Drivers

This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs.

Efficient-Pro Medium and Feed 1 enable rapid and seamless upstream process development and scale-up for CHO-K1 cells

Download the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale.

2024 Life Sciences Industry Outlook

The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond.